The purpose of this study is to assess if using anti-1-amino-3-\[18F\]fluorocyclobutane-1-carboxylic acid (FACBC or fluciclovine) PET scan will be useful in determining if participants are responding to chemotherapy treatment. Investigators will enroll participants whose cancer has been treated with hormone therapy and now the cancer is not responding to the treatment (castration -resistant), and so therefore will be started on chemotherapy. Investigators aim to enroll thirty participants in this study.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Percent Change Assessed by FACBC PET Scan
Timeframe: Baseline, Cycle 1 (Week 2), Cycle 6 (Week 17)
Prostate Specific Antigen Level
Timeframe: Baseline, Cycle 1 (Week 2), Cycle 6 (Week 17)
Number of Participants Responding to Treatment Assessed by MRI
Timeframe: Baseline, Cycle 1 (Week 2), Cycle 6 (Week 17)
Number of Participants Responding to Treatment Assessed by CT Scan
Timeframe: After Cycle 6 (Week 17)
Number of Participants With a Clinical Response Assessed by Bone Scan
Timeframe: Baseline, After Cycle 6 (Week 17)